No content results match your keyword.
Content
You have successfully logged out.
Not registered yet?
Products by Setting – Intensive Care Unit
Patients admitted to ICU who are critically ill, require targeted nutritional support to help navigate through various stages of illness.
B. Braun offer a wide range of parenteral nutrition product solutions that suit varying patient needs in the ICU setting including, central venous infusion, Three-Chamber bags, electrolyte free bags and an Omega-3-Acid triglyceride enriched lipid emulsion, helping to optimise clinical outcomes.
By clicking 'Confirm” you declare that you are a health care professional. If you are a member of the public, we will redirect you to the pages dedicated to you.
Confirm Yes, I am a health care professional. Cancel No, I am not a health care professional.*EPA – Eicosapentaenoic Acid
**DHA – Docosahexaenoic Acid
***TG - Triglycerides
The results of a prospective, multicentre, double-blind study of 159 medical and surgical critically ill patients by Grau- Carmona et al., showed a reduced number of patients with nosocomial infections when receiving Lipidem® compared with patients receiving the standard MCT/LCT lipid emulsion (21 % vs. 37 %; p = 0.035, Fig. 1). Moreover, the results showed that the predicted time free of infections was significantly longer in patients receiving MCT/LCT /Omega-3 vs. standard lipid emulsion (21.4 days vs. 16.2 days; p=0.03).
Reference 2: Grau-Carmona T, Bonet-Saris A, Garcia-de-Lorenzo A, Sanchez-Alvarez C, Rodriguez-Pozo A, Acosta-Escribano J, Minambres E, Herrero-Masesguer JI, Mesejo A ; Influence of n-3 Polyunsaturated Fatty Acids Enriched Lipid Emulsions on Nosocomial Infections and Clinical Outcomes in Critically Ill Patients: ICU Lipids Study; Crit Care Med. 2015 Jan; 43(1):31-9
The results of a randomised, controlled trial in septic patients from Barbosa et al. showed a positive treatment effect of Lipidem® compared to MCT/LCT, reflected in increased plasma eicosapentanoic acid, modified inflammatory cytokine concentrations and improved gas exchange. These changes were associated with a tendency towards shorter length of hospital stay which became significant in the subgroup of ICU survivors.
Reference 3: Vera M. Barbosa, Elizabeth E. Miles, Conceicao Calhua, Estevao Lafuente, Philip C. Calder. Effects of a fish oil containing lipid emulsion on plasma phospholipid fatty acids, inflammatory markers, and clinical outcomes in septic patients: a randomized, controlled clinical trial. Critical Care 2010;14:R5
The results of a prospective, randomised, multicentre trial in patients undergoing major abdominal surgery from Wichmann et al. showed a significantly shorter length of hospital stay in the patient group receiving Lipidem® in comparison with the patient group receiving LCT lipid emulsion (17 days vs. 22 days; p = 0.006)
Reference 4: Matthius W. Wichman, Paul Thul, Hans-Dieter Czarnetzki, Bart J. Morlion, Matthius Kemen, Karl-Walter Jauch. Evaluation of clinical safety and beneficial effects of a fish oil containing lipid emulsion (Lipoplus, MLF541): data from a prospective, randomized, multicenter trial. Critical Care Medicine 2007;35(3):700-706
Provide ready-to-mix formulations of amino acids, glucose and a lipid (Lipidem®).
XX-WEBICU-07-24
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to B. Braun Medical Ltd (tel: 0800 298 0299)
XX-WEBNT-05-24
1. David C Wilson, Pamela Cairns, Henry L Halliday, Mark Reid, Garth McClure Randomised controlled trial of an aggressive nutritional regimen in sick very low birthweight infants Archives of Disease in Childhood 1997;77:F4–F11
